What is the 13F Pro Quality Score for PRLD?

13F Pro ranks Prelude Therapeutics Inc (PRLD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PRLD's current score at https://13fpro.ai/research/PRLD (free sign-up required for the full ranking).

Which hedge funds own the most PRLD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PRLD include ORBIMED ADVISORS, BAKER BROS. ADVISORS, Kynam Capital Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PRLD as soon as new 13F filings post.

Where does 13F Pro source PRLD data?

All Prelude Therapeutics Inc fundamentals and ownership data come directly from SEC EDGAR. Prelude Therapeutics Inc files with the SEC under CIK 1678660. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PRLD in?

Prelude Therapeutics Inc (PRLD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PRLD research updated on 13F Pro?

PRLD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Prelude Therapeutics Inc(PRLD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1678660 PRLD stock profile & AI dashboard →

13F Pro Quality Score

27.0/100

Rank #2,485 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

1.9/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

80.5/100

Revenue Scale

30.0/100

Dilution Risk

3.2/100

PRLD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Prelude Therapeutics Inc (PRLD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRLD at 27.0/100 on a 32-signal composite quality model, placing it at rank #2,485 of 2,879 stocks — the bottom half of the AI-ranked universe. PRLD scores in the top quartile across institutional flow (80.5). Areas of concern include balance sheet strength (1.9) and revenue growth (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Prelude Therapeutics Inc reports quarterly revenue of $4.6M, net income of $-10.4M, free cash flow of $-21.7M. Top institutional holders of PRLD by reported 13-F value include ORBIMED ADVISORS, BAKER BROS. ADVISORS, Kynam Capital Management,, based on the most recent SEC filings. PRLD trades on the Nasdaq exchange and files with the SEC under CIK 1678660. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRLD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Prelude Therapeutics Inc directly from SEC EDGAR. Prelude Therapeutics Inc's 13F Pro composite quality score has ranged between 23 and 37 since 2025, currently 27.0 — an improving long-term trajectory across 12 quarterly and live scoring snapshots.

✦

Fun facts about Prelude Therapeutics Inc

Quirks, history, and lore behind PRLD — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Delaware.
2
The Numbers
Essentially zero product revenue — it runs on grants, equity raises, and hope, with annual operating losses in the tens of millions of dollars. Welcome to early-stage biotech.
3
The History
Founded around 2016 and built by scientists who carved their careers out of cancer epigenetics research, it went public to fund a pipeline it believes can outlast the competition.
4
The Secret
Its entire bet rides on blocking protein degradation machinery — specifically targeting the proteasome pathway in blood cancers where standard treatments have stopped working.
5
The Lore
Its lead program targets hematologic malignancies like multiple myeloma and MDS, hunting patients who've exhausted existing options — the classic high-risk, high-reward biotech play.
6
The Giveaway
A tiny Delaware biotech with a pipeline laser-focused on novel protein homeostasis inhibitors, traded under a ticker that rhymes with "herald" — and its name literally means "introduction" in musical terms.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$4.6M

Net Income

Q1 2026

$-10.4M

Free Cash Flow

Q1 2026

$-21.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+73.4% YoY

$12.1MFY 2025

FY21 —FY23 —FY24 $7.0MFY25 $12.1M

Net Income

+21.8% YoY

$-99.5MFY 2025

FY21 $-111.7MFY23 $-121.8MFY24 $-127.2MFY25 $-99.5M

Operating Income

+25.2% YoY

$-104.6MFY 2025

FY21 $-113.7MFY23 $-132.3MFY24 $-139.7MFY25 $-104.6M

EPS (Diluted)

+23.2% YoY

$-1.29FY 2025

FY21 $-2.43FY23 $-2.02FY24 $-1.68FY25 $-1.29

Total Assets

-19.5% YoY

$141.3MFY 2025

FY21 $305.1MFY23 $277.7MFY24 $175.5MFY25 $141.3M

Op. Cash Flow

+45.3% YoY

$-56.3MFY 2025

FY21 $-83.5MFY23 $-107.1MFY24 $-102.9MFY25 $-56.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$12.1M +73.4%	$7.0M	—	—	—	—
Net Income	$-99.5M +21.8%	$-127.2M -4.4%	$-121.8M -9.1%	$-111.7M -96.2%	$-56.9M -106.5%	$-27.6M
Operating Income	$-104.6M +25.2%	$-139.7M -5.6%	$-132.3M -16.3%	$-113.7M -93.5%	$-58.8M -109.1%	$-28.1M
EPS (Diluted)	$-1.29 +23.2%	$-1.68 +16.8%	$-2.02 +16.9%	$-2.43	—	—
Total Assets	$141.3M -19.5%	$175.5M -36.8%	$277.7M -9.0%	$305.1M +36.5%	$223.6M +922.3%	$21.9M
Operating Cash Flow	$-56.3M +45.3%	$-102.9M +3.9%	$-107.1M -28.2%	$-83.5M -80.9%	$-46.2M -79.9%	$-25.7M

AI Insight: PRLD Financial Trends

Prelude's cash burn is shrinking fast — net loss nearly halved from $35M in Q2 2024 to $10M in Q1 2026 — but equity erosion continues.

• Net loss narrowed sharply from $-35M in Q2 2024 to $-10M in Q1 2026, the smallest quarterly loss in the dataset.

• Operating cash flow turned positive at $23M in Q4 2025, the only quarter with positive OCF, though Q1 2026 reverted to $-22M.

• Equity has declined steadily from $182M in Q2 2024 to $60M in Q1 2026, an erosion of $122M over eight quarters.

• Revenue remained sporadic — absent in most quarters, appearing at $4M in Q4 2024, $6M in Q4 2025, and $5M in Q1 2026.

⚠ Equity at $60M in Q1 2026 with recurring $10–35M quarterly losses — runway is a key concern absent new financing.

⚠ Revenue visibility remains low; consecutive quarters of $5–6M could signal a licensing deal worth tracking for sustainability.

⚠ Q1 2026 operating cash outflow of $-22M after Q4 2025's positive $23M warrants monitoring — one-quarter anomaly or trend reversal?

AI Insight: PRLD Ratio Trends

Return metrics remain deeply negative but ROE and ROA show meaningful sequential improvement in Q1 2026, suggesting capital burn may be decelerating.

• ROE improved from -164.7% in Q2 2025 to -69.0% in Q1 2026, the least negative reading in the dataset.

• ROA recovered from a trough of -90.8% in Q1 2025 to -34.7% in Q1 2026, a significant sequential improvement.

• OpMargin and NPM are absent across all periods, reflecting zero or near-zero revenue typical of a clinical-stage biotech.

⚠ ROIC remains deeply negative at -94.2% in Q1 2026, deteriorating from -81.6% in Q2 2024 — capital efficiency has not improved.

⚠ TTM ROE of -129.3% is worse than the Q1 2026 quarterly figure, signaling prior quarters still weigh heavily on trailing returns.

⚠ D/E data is entirely absent; leverage structure and runway remain unquantifiable from this dataset alone.

Get alerted when PRLD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Prelude Therapeutics Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PRLD

ORBIMED ADVISORS LLC
$37.3M10,909,256 sh
BAKER BROS. ADVISORS LP
$34.6M10,123,824 sh
Kynam Capital Management, LP
$5.4M1,592,551 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.2M1,230,406 sh
EcoR1 Capital, LLC
$3.2M947,049 sh
TWO SIGMA INVESTMENTS, LP
$3.2M923,626 sh
SPHERA FUNDS MANAGEMENT LTD.
$1.9M558,339 sh
MILLENNIUM MANAGEMENT LLC
$1.3M382,737 sh
MARSHALL WACE, LLP
$1.2M358,906 sh
MORGAN STANLEY
$1.1M322,161 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$37.3M	10,909,256
BAKER BROS. ADVISORS LP	$34.6M	10,123,824
Kynam Capital Management, LP	$5.4M	1,592,551
VANGUARD CAPITAL MANAGEMENT LLC	$4.2M	1,230,406
EcoR1 Capital, LLC	$3.2M	947,049
TWO SIGMA INVESTMENTS, LP	$3.2M	923,626
SPHERA FUNDS MANAGEMENT LTD.	$1.9M	558,339
MILLENNIUM MANAGEMENT LLC	$1.3M	382,737
MARSHALL WACE, LLP	$1.2M	358,906
MORGAN STANLEY	$1.1M	322,161

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PRLD on your watchlist

Track score changes the day Prelude Therapeutics Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PRLD a good stock to buy?

13F Pro's AI-powered analysis of Prelude Therapeutics Inc (PRLD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRLD are available on the PRLD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PRLD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRLD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Prelude Therapeutics Inc's investment landscape.